Cargando…
Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings—A Case Report and Literature Review
Immune checkpoint inhibitors (ICIs) represent a major advance in cancer treatment. The lowered immune tolerance induced by ICIs brought to light a series of immune-related adverse events (irAEs). Pembrolizumab belongs to the ICI class and is a humanized IgG4 anti-PD-1 antibody that blocks the intera...
Autores principales: | Giovannini, Elena, Bonasoni, Maria Paola, D’Aleo, Michele, Tamagnini, Ione, Tudini, Matteo, Fais, Paolo, Pelotti, Susi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342066/ https://www.ncbi.nlm.nih.gov/pubmed/37446095 http://dx.doi.org/10.3390/ijms241310919 |
Ejemplares similares
-
Pembrolizumab‐induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer
por: Todo, Maki, et al.
Publicado: (2019) -
Editorial Comment to Pembrolizumab‐induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer
por: Tomisaki, Ikko
Publicado: (2019) -
Infection Induced Fetal Inflammatory Response Syndrome (FIRS): State-of- the-Art and Medico-Legal Implications—A Narrative Review
por: Giovannini, Elena, et al.
Publicado: (2023) -
Nivolumab-Induced Myasthenia Gravis Concomitant With Myocarditis, Myositis, and Hepatitis
por: Bawek, Sawyer J, et al.
Publicado: (2021) -
Pembrolizumab‐induced myasthenia gravis with myositis in a patient with lung cancer
por: Hibino, Makoto, et al.
Publicado: (2018)